Want to see MLYS full AI Analyst Report?
MLYS Stock Chart & Stats
$30.58
-$0.99(-7.63%)
At close: 4:00 PM EST
$30.58
-$0.99(-7.63%)
Day’s Range― - ―
52-Week Range$12.59 - $47.65
Previous CloseN/A
Volume137.34K
Average Volume (3M)1.95M
Market Cap
$2.50B
Enterprise Value$1.55B
Total Cash (Recent Filing)$646.06M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 18, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.05
Shares Outstanding88,158,480
10 Day Avg. Volume1,164,085
30 Day Avg. Volume1,945,399
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)3.80
Price to Sales (P/S)0.00
P/FCF Ratio-17.24
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-73.96K
Enterprise Value/Ebitda-10.24
Forecast
1Y Price Target
$50.40Price Target Upside64.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory MilestoneNDA acceptance with a defined PDUFA date materially reduces the regulatory timing uncertainty that typically plagues clinical‑stage biotechs. This milestone permits focused resource allocation for label negotiation, launch planning, and partner decisions over the next 6–18 months, improving strategic clarity and de‑risking near‑term development cadence.
Broad Clinical Data PackageA robust dataset from five trials and demonstrable, durable blood‑pressure reductions across varied cohorts strengthens regulatory and payer arguments and reduces the risk of narrow labeling. This durable clinical evidence supports differentiated positioning versus competitors and aids long‑term prescriber uptake and reimbursement arguments.
Strong Cash Position And RunwayA sizable cash balance and stated runway into 2028 provide the company multi‑year flexibility to complete regulatory activities, build prelaunch commercial capabilities, and engage payers without immediate financing pressure. This funding buffer materially lowers near‑term execution risk and supports deliberate commercialization choices.
Bears Say
Persistent Cash BurnSustained large operating and free cash outflows indicate the company remains dependent on external capital to fund operations. Over the next 2–3 years, continued negative FCF increases the probability of dilution or debt draws, constraining strategic optionality and elevating financing risk as commercialization investments accelerate.
Rising Prelaunch G&ASharp increases in G&A driven by personnel and professional fees reflect an accelerated and permanent cost base buildup for commercial readiness. If launch uptake or partnering falls short, these fixed prelaunch commitments will pressure margins and cash needs, making sustained profitability and capital efficiency harder to achieve.
Higher Leverage And Upfront CommitmentsConsolidating global rights via a $200M repurchase obligation and adding a $500M secured facility materially changes capital structure. The loan’s covenants and asset security (including IP) increase default and operational constraint risks, potentially limiting strategic flexibility and increasing downside for equity holders if sales or approval timelines slip.
Mineralys Therapeutics, Inc. News
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $12.59 and its highest was $47.65 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Mineralys Therapeutics, Inc.’s market cap is $2.50B.
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 35 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on May 06, 2026. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.472 by $0.002.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 88,158,480 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.472. Following the earnings report the stock price went down -2.556%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MLYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mineralys Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.40 (64.81% Upside)
$50.40 (64.81% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 514.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
93.85%
12-Months-Change
Fundamentals
Return on Equity
-27.92%
Trailing 12-Months
Asset Growth
83.94%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.
MLYS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive progress on the clinical and regulatory front with NDA acceptance and a clear PDUFA date, supported by a broad dataset and active prelaunch preparations. Financially, the company retains a substantial cash balance with runway into 2028 and showed reduced R&D spend following completion of pivotal work. Offsetting risks include a sizeable increase in G&A/prelaunch costs, continued quarterly net losses, competitive timing and pricing pressure from AstraZeneca’s expected earlier launch, and unresolved partnering and labeling/pricing uncertainties. On balance, the company appears well positioned operationally and clinically, but near-term commercial and financial execution risks remain.View all MLYS earnings summariesMLYS Stock 12 Month Forecast
Average Price Target
$50.40
▲(64.81% Upside)
Technical Analysis
Ownership Overview
25.25% Insiders
17.08% Mutual Funds
0.13% Other Institutional Investors
46.37% Public Companies and
Individual Investors